Below, we outline the most significant challenges and ethical considerations surrounding AI in precision medicine.
AI interpretability challenges
One of the primary criticisms of AI in genomics is its "black box" nature. AI systems often produce outputs without providing clear explanations or justifications. In clinical diagnostics and trial design, understanding not only "what" prediction is made but also "why" is essential for informed decision-making.
This matters particularly in precision medicine, where AI-driven outputs can directly influence which patients are identified as eligible, how biomarker data is interpreted, and which treatment pathways are recommended. When clinicians and study teams cannot trace the reasoning behind a model's output, it becomes difficult to validate decisions, identify errors, or build confidence across the research lifecycle.
The challenge extends to regulatory contexts as well. As AI systems move from research tools to components of clinical decision support and diagnostic workflows, the expectation for explainability increases. Building effective and reliable AI in healthcare requires not only accurate outputs but also the ability to communicate how those outputs were derived.
Bias in AI training data
Genomic and health data are shaped by socioeconomic status, lifestyle, geography, and healthcare access. When AI models are trained on datasets that reflect these disparities, they risk encoding and amplifying them. In precision medicine, this has direct consequences for which patients are identified, how eligibility is assessed, and whether study populations reflect the diversity of the disease being studied.
For example, the AI system DeepGestalt displayed significant accuracy discrepancies in identifying Down syndrome among individuals of different ancestries. This illustrates how training data composition directly affects model performance across populations.
In trial design, unchecked bias can constrain patient pools, produce skewed datasets, and undermine the generalizability of study results. Addressing this requires deliberate effort at multiple stages: curating diverse training datasets, auditing model outputs across demographic groups, and establishing accountability frameworks that surface and correct bias before it compounds downstream.
Phenotypic data collection
AI models in precision medicine depend on both genetic and phenotypic data to produce meaningful outputs. However, phenotypic data presents a distinct challenge. Unlike genomic sequences, which are inherently structured and quantifiable, phenotypic data is often qualitative, inconsistently recorded, and difficult to standardize across sources and geographies.
This creates a bottleneck. Without large-scale, high-quality phenotypic datasets, AI models lack the training inputs needed to reliably predict outcomes or stratify patients. The result is models that may perform well in narrow contexts but fail to generalize across diverse patient populations.
Biobank-scale efforts such as the UK Biobank and the All of Us Research Program are beginning to address this gap by generating large, structured datasets that combine genetic and phenotypic information. These resources are improving the foundation on which AI systems in healthcare are built, but the challenge of scalable, standardized phenotypic collection remains a limiting factor for many precision medicine applications.
Data privacy and patient consent
As AI becomes more embedded in healthcare and clinical research, questions around the sourcing and privacy of training data grow more urgent. AI models trained on patient data, including genomic information, raise specific concerns about how that data was consented, how it is stored, and whether its use extends beyond what participants were originally informed about.
Regulatory frameworks such as HIPAA in the United States and GDPR in the European Union establish baseline requirements for data consent and privacy, but their application to AI-generated health insights remains an area of active interpretation and policy development.
In precision medicine, where genetic data is central, these concerns are particularly acute. Participants may consent to testing for a specific study but may not fully understand how their data could be used to train predictive models or inform future research. Without clear, transparent consent processes, this gap erodes trust and creates compliance risk.
Ethical considerations also extend to patient autonomy, shared decision-making, and the potential for algorithmic errors in high-stakes clinical contexts. Establishing accountability frameworks, alongside transparency about data use, is essential for maintaining participant confidence and meeting the expectations of regulators and ethics committees.
Regulatory frameworks and ethical guidelines
The approval of a growing number of AI algorithms by regulatory bodies introduces a need for comprehensive guidelines to navigate the ethical and technical challenges these tools present. Across multiple jurisdictions, regulatory agencies are actively developing frameworks to govern how AI is validated, deployed, and monitored in clinical settings.
In the United States, for example, multiple federal agencies, including the FDA, the Office of the National Coordinator for Health IT, and the Centers for Medicare and Medicaid Services, are each addressing different dimensions of AI governance in healthcare. This creates a complex, multi-layered regulatory environment that sponsors and developers must navigate carefully.
For precision medicine programs, the implications are significant. AI tools used in patient identification, biomarker analysis, or eligibility screening must meet evolving standards for interpretability, fairness, and data governance. Best practices for transparency and bias mitigation, combined with structured guidance, are essential for the responsible development and implementation of AI-driven diagnostic tools.
AI is already influencing how genomic data is interpreted, how patients are stratified, and how clinical programs are designed. But the challenges outlined here — from interpretability and bias to privacy, data quality, and regulatory complexity — are not peripheral concerns. They are structural issues that directly affect the reliability of AI-driven workflows in precision medicine.
For sponsors and clinical teams, addressing these challenges is not optional. It requires deliberate attention to data governance, model transparency, and regulatory alignment at every stage of the research lifecycle. The organizations that invest in this foundation now will be better positioned to use AI responsibly and effectively as precision medicine programs grow in scale and complexity.
To learn more, download our whitepaper, "Data-driven healthcare: How artificial intelligence and machine learning are transforming genomics."